TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32216555
Drug: Colistin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin (20 mg/kg)
Study: 32216555
Drug: Tylosin (55
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tylosin (55 mg/kg)
Study: 32216555
Drug: Chlortetracycline (CTC,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlortetracycline (CTC, 55 mg/kg)
Study: 35641878
Drug: IV lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV lignocaine infusion (1.5 mg/kg at induction followed by 1.5 mg/kg/h for 1 hour in PACU)
Study: 35641878
Drug: IV lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV lignocaine infusion
Study: 35641878
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline IV infusion
Study: 35465764
Drug: Acknowledgment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acknowledgment of vaccine hesitancy
Study: 33125753
Drug: SAR247799 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR247799 1 mg
Study: 33125753
Drug: SAR247799 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR247799 5 mg
Study: 33125753
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 mg (positive control)
Study: 33257343
Drug: Hyoscine butylbromide
Normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine butylbromide (10 mg orally)
Study: 33257343
Drug: Acetaminophen (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (15 mg/kg orally, max 975 mg)
Study: 33244719
Drug: Laparoscopic surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic surgery for rectal cancer
Study: 34020931
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) plus docetaxel (75 mg/m2 q3w for ten cycles)
Study: 32313142
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) plus docetaxel
Study: 32392455
Drug: Lurasidone 20-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 20-80 mg
Study: 95358022
Drug: S +
Normalized name: K-Y Yours + Mine
Approvals — FDA: no, EMA: no, PMDA: no
Description: S + preS2 vaccine
Study: 95358022
Drug: S vaccine
Normalized name: Mumps vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: S vaccine
Study: 95358022
Drug: Any vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any vaccine used
Study: 34889883
Drug: Injection Cerebrolysin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection Cerebrolysin 5 mL diluted in 100 mL Normal Saline over 30 minutes once a day for 21 days postoperatively
Study: 33883195
Drug: Basal-bolus insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal-bolus insulin (BBI) regimen
Study: 33883195
Drug: Fixed ratio
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed ratio of basal insulin plus GLP-1RA (fixed-combo group)
Study: 33883195
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin plus SGLT2 inhibitor (gliflo-combo group)
Study: 33734144
Drug: Intravenous Opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Opioid Analgesia (PCA-M)
Study: 32037263
Drug: 12-week hospital
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week hospital based physical therapy (intervention group, n=8)
Study: 32453406
Drug: Withdrawal plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal plus preventive treatment
Study: 32453406
Drug: Preventive treatment
Normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive treatment without withdrawal
Study: 32453406
Drug: Withdrawal with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal with optional preventive treatment 2 months after withdrawal
Study: 36942420
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of exercise and liraglutide 3.0 mg/d
Study: 38227621
Drug: Liraglutide 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 3.0 mg/d
Study: 32342247
Drug: Perioperative GL
Normalized name: GL-2045
DrugBank: GL-2045 (DB16971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative GL group receiving 100 mL of 5% glucose solution immediately after local anesthesia
Study: 32342247
Drug: Postoperative GL
Normalized name: GL-2045
DrugBank: GL-2045 (DB16971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative GL group receiving 100 mL of 5% glucose solution immediately after surgery completion
Study: 32342247
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving glucose-free sodium lactate Ringer's solution
Study: 34080920
Drug: Mirtazapine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (15 mg at bedtime)
Study: 35775129
Drug: Simultaneous integrated
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous integrated boost (SIB) protocol with 4.45 Gy dose increase
Study: 33541062
Drug: Pendulum treatment
Normalized name: Aconitum pendulum root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pendulum treatment for molar distalization over 6 months
Study: 33541062
Drug: Pendulum treatment
Normalized name: Aconitum pendulum root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pendulum treatment for molar distalization
Study: 33541062
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment) after one year
Study: 32865062
Drug: Chemotherapy perfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy perfusion
Study: 32396592
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice drink (375 mg total flavan‐3‐ols)
Study: 32396592
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice drink (716 mg total flavan‐3‐ols)
Study: 32396592
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice drink (1131 mg total flavan‐3‐ols)
Study: 32396592
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice drink (1396 mg total flavan‐3‐ols)
Study: 32396592
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice drink (1741 mg total flavan‐3‐ols)
Study: 32378071
Drug: Modified FOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified FOLFOX6 (oxaliplatin in combination with 5‐fluorouracil and l‐leucovorin)
Study: 33415858
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (Escitalopram Oxalate tablets 5-20 mg/d)
Study: 34836079
Drug: EXCO (exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: EXCO (exercise + 2 g/day oil from Calanus finmarchicus)
Study: 34836079
Drug: CON (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: CON (control group, no treatment)
Study: 34102553
Drug: Phone-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phone-based intervention under nurse guidance including home BP monitoring, medication reminders, and education on hypertension delivered weekly for 12 months.
Study: 35217670
Drug: albendazole and
Normalized name: Albendazole and ivermectin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: albendazole and ivermectin combination therapy
Study: 36944461
Drug: Taurolidine-citrate-heparin lock
Normalized name: heparin / taurolidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurolidine-citrate-heparin lock solution
Study: 34903116
Drug: Fluoridated milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoridated milk (F-milk) adjunctive to 1000-ppm fluoride dentifrice (FD)
Study: 34903116
Drug: Non-fluoridated milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-fluoridated milk (non-F-milk) adjunctive to 1000-ppm fluoride dentifrice (FD)
Study: 32959604
Drug: TB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TB treatment under BRAC program
Study: 32212418
Drug: IV relebactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV relebactam 1150 mg
Study: 33561904
Drug: Virgin olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virgin olive oil enriched with its own phenolic compounds (FVOO)
Study: 33561904
Drug: Virgin olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virgin olive oil enriched with additional phenolic compounds from thyme (FVOOT)
Study: 32581088
Drug: Rituximab (4×375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (4×375 mg/m2) and glucocorticoids (higher or lower dose regimen, reducing from either 1 mg/kg/day or 0.5 mg/kg/day to 10 mg/day by 4 months)
Study: 35340062
Drug: Risedronate daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate daily
Study: 32052026
Drug: Bifenthrin barrier
Normalized name: Bifenthrin
DrugBank: Bifenthrin (DB15056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifenthrin barrier spray and larval habitat management (LHM)
Study: 32052026
Drug: Bifenthrin barrier
Normalized name: Bifenthrin
DrugBank: Bifenthrin (DB15056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifenthrin barrier spray alone
Study: 32954647
Drug: Qishen Yiqi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qishen Yiqi dripping pills (QSYQ)
Study: 32506278
Drug: Systemic erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic erythropoietin (10,000 units twice a day for 3 days)
Study: 32506278
Drug: Oral steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroids (prednisone 75 mg daily tapered off in 6 weeks)
Study: 36050629
Drug: US-guided internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-guided internal superior laryngeal nerve block with 2 ml of 0.25% ropivacaine bilaterally immediately after operation
Study: 34182375
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (BAC = 0 g/l)
Study: 37369125
Drug: Mifepristone 600
Normalized name: Mifepristone 600 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 600 mg/day for 1 week
Study: 33318373
Drug: 10-kHz High-frequency
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-kHz High-frequency Therapy (HF10 Therapy)
Study: 32885341
Drug: SRP followed
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP followed by laser therapy of the periodontal pockets with 980 nm diode laser, 1 W, continuous wave mode, 20 s per tooth side, repeated twice at 5–7 day intervals.
Study: 34105614
Drug: Orofacial myofunctional
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orofacial myofunctional therapy associated with photobiomodulation
Study: 34105614
Drug: Orofacial myofunctional
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orofacial myofunctional therapy associated with inactive photobiomodulation (placebo)
Study: 36746160
Drug: Metformin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1000 mg twice daily)
Study: 35843287
Drug: Clear fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear fluids only for 18 hours before CE and simethicone 200 mg in 150 mL water immediately before CE (Arm A)
Study: 35843287
Drug: Clear fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear fluids only for 18 hours before CE and simethicone 200 mg in 150 mL water immediately before CE + 2 L of polyethylene glycol (PEG) 12 hours before CE (Arm B)
Study: 35843287
Drug: Clear fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear fluids only for 18 hours before CE and simethicone 200 mg in 150 mL water immediately before CE + 1 L PEG + sodium ascorbate 3 hours before CE (Arm C)
Study: 33006767
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid (TCS) - mometasone furoate 0.1% ointment + dummy NB‐UVB
Study: 33006767
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment - TCS + NB‐UVB
Study: 34401368
Drug: internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-delivered cognitive behavioral therapy for insomnia (iCBT-i)
Study: 36028858
Drug: Givosiran (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Givosiran (2.5 mg/kg monthly)
Study: 36167599
Drug: Degarelix (240-80-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Degarelix (240-80-80 mg) + Apalutamide (240 mg/d) for 3 months
Study: 33938653
Drug: anterior QLB
Approvals — FDA: no, EMA: no, PMDA: no
Description: anterior QLB (n=25) with preoperative ropivacaine 3.75 mg/mL, 20 mL bilaterally
Study: 33938653
Drug: placebo QLB
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo QLB (n=22) with preoperative isotonic saline, 20 mL bilaterally
Study: 33938653
Drug: controls (n=23)
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: controls (n=23) given only standard intravenous and oral analgesia
Study: 35704475
Drug: ASC-enriched fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASC-enriched fat grafting (10 × 10^6 ASCs/mL fat graft)
Study: 33408315
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rosuvastatin once daily
Study: 33408315
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg rosuvastatin once daily
Study: 33715955
Drug: Regular coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular coffee (80 mL)
Study: 33715955
Drug: Decaffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated coffee (80 mL, placebo)
Study: 32787879
Drug: n-3PUFA supplementation
Normalized name: (+/-)-N-methylephedrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3PUFA supplementation (3.3 g/day)
Study: 32787879
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil placebo (PLA) (3.0 g/day)
Study: 32424499
Drug: Brace treatment
Normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brace treatment only group (Group 1)
Study: 36166771
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg daily for 90 days
Study: 33159533
Drug: Home-based impact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based impact exercise intervention (16 weeks, progressively increasing to 50 multi-directional unilateral hops on each leg daily)
Study: 36201325
Drug: GAL (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAL (0.4 g.min‐1)
Study: 36201325
Drug: GAL+GLU (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAL+GLU (0.4 g.min‐1 galactose and 0.8 g.min‐1 glucose)
Study: 36201325
Drug: GLU (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLU (0.8 g.min‐1)
Study: 35881895
Drug: SP16 (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP16 (0.2 mg/kg)
Study: 33956804
Drug: SP16 (0.0125
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP16 (0.0125 mg/kg and 0.05 mg/kg)
Study: 35507955
Drug: Momordica charantia
Normalized name: MOMORDICA CHARANTIA STEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Momordica charantia (MC) 2000 mg/day for 12 weeks
Study: 32377302
Drug: Plasma selenium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma selenium concentrations in MetS group (93.88 μg/L)
Study: 32377302
Drug: Quartile 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quartile 1 (<82.36 μg/L)
Study: 32377302
Drug: Quartile 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quartile 2 (82.37-92.66 μg/L)
Study: 32377302
Drug: Quartile 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quartile 3 (92.67-103.52 μg/L)
Study: 32588788
Drug: Hemospray therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemospray therapy
Study: 33075037
Drug: Decision rule-guided
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decision rule-guided antibiotic prescription (n = 402)
Study: 32196636
Drug: Structured physical
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured physical activity (PA) intervention including two center-based plus three to four home-based exercise sessions per week, aiming for 150 minutes of walking weekly for 2.5 years on average
Study: 33183320
Drug: BUDCA (berberine
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUDCA (berberine ursodeoxycholate) at a dose of 2000 mg per day for 28 days
Study: 35428650
Drug: Treg therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treg therapy (TR001)
Study: 33998561
Drug: Purposeful activity-based
Normalized name: Corona Multi-Purpose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purposeful activity-based electrical stimulation therapy (PA‐EST) for 3 months (phase 1)
Study: 33215554
Drug: Internet-Delivered Cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-Delivered Cognitive Behavioral Therapy (Living with Deadly Thoughts)
Study: 33306414
Drug: RRx-001 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRx-001 (4 mg once weekly until progression)
Study: 33306414
Drug: Etoposide platinum
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide platinum (EP) chemotherapy (etoposide 100 mg/m2 IV on days 1-3, cisplatin 80 mg/m2 IV on day 1 or carboplatin AUC 5-6 IV on day 1)
Study: 34999207
Drug: Vascepa 2
Normalized name: Vascepa
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Vascepa 2 g twice daily
Study: 34999207
Drug: Fenofibrate in
Normalized name: Product containing fenofibrate in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate in patients with baseline triglycerides <250 mg/dL
Study: 34999207
Drug: Fenofibrate in
Normalized name: Product containing fenofibrate in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate in patients with baseline triglycerides ≥250 mg/dL
Study: 35751891
Drug: Kundur (Boswellia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kundur (Boswellia serrata) 1g vaginal insert daily for 21 days
Study: 35751891
Drug: Miconazole (2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miconazole (2% w/w) 100mg vaginal suppository daily for 7 days
Study: 34491649
Drug: Bo's abdominal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bo's abdominal acupuncture (combined with methotrexate treatment)
Study: 34491649
Drug: Methotrexate tablets
Normalized name: Methotrexate Tablets
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate tablets (5 mg once a week)
Study: 35842108
Drug: Pharmacotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy with paroxetine or venlafaxine extended release
Study: 35842108
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PE and medication
Study: 35918624
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg every 8 hours (control group)
Study: 35918624
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg at breakfast and lunch, placebo at dinner (experimental group)
Study: 35643520
Drug: Ma’s bamboo‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ma’s bamboo‐based medicinal moxibustion therapy
Study: 32133778
Drug: Triprolidine 2.5
Normalized name: triprolidine 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triprolidine 2.5 mg + Pseudoephedrine 60 mg
Study: 36472675
Drug: Family-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based treatment involving 10–12 sessions attended by the mother and an identified family member (father) at each session.
Study: 34882193
Drug: Fixed orthodontic
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed orthodontic treatment after periodontal stabilization
Study: 36422809
Drug: DWP16001 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP16001 (2 mg) + Metformin (1000 mg bid for 7 days)
Study: 36422809
Drug: Metformin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1000 mg bid for 7 days)
Study: 32100719
Drug: Subcutaneous collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous collagen injection (Group A, n = 10)
Study: 32100719
Drug: Periradicular collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periradicular collagen injection (Group B, n = 10)
Study: 32100719
Drug: Epidural collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural collagen injection (Group C, n = 10)
Study: 616062701
Drug: Mitosis Kinase
Normalized name: Kinase (enzyme-activating), uro-urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitosis Kinase Score (MKS) before treatment
Study: 616062701
Drug: Mitosis Kinase
Normalized name: Kinase (enzyme-activating), uro-urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitosis Kinase Score (MKS) in paired samples after treatment
Study: 616062701
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MKS and p21 expression
Study: 35171317
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g meropenem, 3-h infusion
Study: 35171317
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g meropenem, 3-h infusion